

# Biased signaling and L1 penalization Romain Yvinec

# ▶ To cite this version:

Romain Yvinec. Biased signaling and L1 penalization. ODE Modelling in Systems Biology, Sep 2017, freibourg, Germany. hal-02785169

# HAL Id: hal-02785169 https://hal.inrae.fr/hal-02785169

Submitted on 4 Jun2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

#### Biased signaling and L1 penalization Towards a system biology definition of drugs selectivity

Romain Yvinec

BIOS, INRA Centre Val-de-Loire

What is biased signaling?

Some examples

Bias calculus - standard method : operational model

Some extension to bias calculus

Biased signaling using dynamical model

#### What is biased signaling?

Some examples

Bias calculus - standard method : operational model

Some extension to bias calculus

Biased signaling using dynamical model

#### Functional selectivity

From Wikipedia, the free encyclopedia

Not to be confused with binding selectivity.

**Functional selectivity** (or "agonist trafficking", "biased agonism", "biased signalling", "ligand bias", and "differential engagement" ) is the ligand-dependent selectivity for certain signal transduction pathways in one and the same receptor. This can be present when a receptor has several possible signal transduction pathways. To which degree each pathway is activated thus depends on which ligand binds to the receptor.<sup>[1]</sup>





#### Functional selectivity

From Wikipedia, the free encyclopedia

Not to be confused with binding selectivity.

**Functional selectivity** (or "agonist trafficking", "biased agonism", "biased signalling", "ligand bias", and "differential engagement" ) is the ligand-dependent selectivity for certain signal transduction pathways in one and the same receptor. This can be present when a receptor has several possible signal transduction pathways. To which degree each pathway is activated thus depends on which ligand binds to the receptor.<sup>[1]</sup>

 Ligand-specific activity in one receptor





#### Functional selectivity

From Wikipedia, the free encyclopedia

Not to be confused with binding selectivity.

**Functional selectivity** (or "agonist trafficking", "biased agonism", "biased signalling", "ligand bias", and "differential engagement" ) is the ligand-dependent selectivity for certain signal transduction pathways in one and the same receptor. This can be present when a receptor has several possible signal transduction pathways. To which degree each pathway is activated thus depends on which ligand binds to the receptor.<sup>[1]</sup>

 Several potential pathways associate to a given receptor





#### Functional selectivity

From Wikipedia, the free encyclopedia

Not to be confused with binding selectivity.

**Functional selectivity** (or "agonist trafficking", "biased agonism", "biased signalling", "ligand bias", and "differential engagement" ) is the ligand-dependent selectivity for certain signal transduction pathways in one and the same receptor. This can be present when a receptor has several possible signal transduction pathways. To which degree each pathway is activated thus depends on which ligand binds to the receptor.<sup>[1]</sup>

 Differential activation of certain pathways





- Biased agonism is a key concept to be distinguish from
  - Partial or full agonist.
  - Antagonist, inverse agonist.
  - Affinity  $(K_d)$ , potency  $(EC_{50})$ , efficacy  $(E_{max})$ .


- ♦ Biased agonism is a key concept to be distinguish from
  - Partial or full agonist.
  - Antagonist, inverse agonist.
  - Affinity  $(K_d)$ , potency  $(EC_{50})$ , efficacy  $(E_{max})$ .
- A bias might be context-dependent (cell type, physiological state, etc.)

Biased agonism is a key concept to be distinguish from

- Partial or full agonist.
- Antagonist, inverse agonist.
- Affinity  $(K_d)$ , potency  $(EC_{50})$ , efficacy  $(E_{max})$ .
- A bias might be context-dependent (cell type, physiological state, etc.)
- ◊ Biased agonism is becoming a major tool in drug discovery.
- $\Rightarrow$  Candidate screening requires to accurately quantify bias.

A receptor may adopt several spatial conformations, each of which has different activation pathway profiles.

 Conformational selectivity = Ligand-specific modification of the energetic landscape, changing affinities and efficacies of signaling patways.






Kenakin, J Pharmacol Exp Ther (2011)

# Theoretical foundation

A receptor may adopt several spatial conformations, each of which has different activation pathway profiles.


- Conformational selectivity = Ligand-specific modification of the energetic landscape, changing affinities and efficacies of signaling patways.
- Similar concept : modulating bias





Kenakin and Christopoulos, Nat. Rev. Drug Discov. (2013)

To speak about signaling bias, one necessarily needs **two** ligands and **two** responses, in a **same** cellular context.



 $\Rightarrow$  We always compare a ligand with respect to a reference one.

#### What is biased signaling?

#### Some examples

Bias calculus - standard method : operational model

Some extension to bias calculus


Biased signaling using dynamical model

# Serotonine receptor $5 - HT_{2C}$

- Quipazine is biaised towards PI accumulation with respect to AA production, compared to the reference agonist DOI.
- LSD is not biased.




Berg et al., *Mol. Pharmacol.* (1998)



# Serotonine receptor $5 - HT_{2C}$


- Quipazine is biaised towards PI accumulation with respect to AA production, compared to the reference agonist DOI.
- LSD is not biased.
- Bias due to an E<sub>max</sub> difference.





Berg et al., *Mol. Pharmacol.* (1998)

# Serotonine receptor $5 - HT_{2A}$




(R) - 2C - B - CB is biaised towards *PI* accumulation with respect to *AA* production, *compared to the reference agonist DOB*.



Urban et al., J Pharmacol Exp Ther (2007)

# Serotonine receptor $5 - HT_{2A}$



(R) - 2C - B - CB is biaised towards *PI* accumulation with respect to *AA* production, *compared to the reference agonist DOB*.

• Bias due to an  $EC_{50}$  difference.




Urban et al., J Pharmacol Exp Ther (2007)

### Steroidogenesis modeulated by NAM

Some negative allosteric modulators (NAM) can biased Progesterone production with respect to Testosterone production, under stimulation of LH/CG receptor by hCG.

Ayoub et al., *Mol. Cell. Endocrinol* (2016)




# Steroidogenesis modeulated by NAM

Some negative allosteric modulators (NAM) can biased Progesterone production with respect to Testosterone production, under stimulation of LH/CG receptor by hCG.

> Selective (biased) allosteric modulation



Ayoub et al., *Mol. Cell. Endocrinol* (2016)






Many GPCR's are known to have biased ligands ( $G / \beta$ -arrestin)



Kenakin, J Pharmacol Exp Ther (2011)



Kenakin, *Chem Rev* (2017)



What is biased signaling?

Some examples

Bias calculus - standard method : operational model

Some extension to bias calculus

Biased signaling using dynamical model


# Operational model

Dose-response data are fitted with the function

$$y = E_{tot} \frac{\tau^n[L]^n}{([L] + K_A)^n + \tau^n[L]^n}.$$

- Response at equilibrium of a Michaelis-Menten type model.
- K<sub>A</sub> = Dissociation constant of the couple Ligand/Receptor





Dose-response data are fitted with the function

$$y = E_{tot} \frac{\tau^n [L]^n}{([L] + K_A)^n + \tau^n [L]^n} \,.$$

For n = 1,

•  $EC_{50} = \frac{K_A}{\tau+1}$ 

• Efficacy 
$$y_{\infty}/E_{tot} = \frac{\tau}{\tau+1}$$







Black and Leff, *Proc. R. Soc. Lond. B* (1983) Dose-response data are fitted with the function

$$y = E_{tot} \frac{\tau^n [L]^n}{([L] + K_A)^n + \tau^n [L]^n} \,.$$

For n = 1,

• 
$$EC_{50} = \frac{K_A}{\tau+1}$$


• Efficacy 
$$y_{\infty}/E_{tot} = \frac{\tau}{\tau+1}$$

Then, we define


Transduction coefficient :

$$R := \log\left(\frac{\tau}{K_A}\right)$$

J. W. Black and P. Leff




#### Bias definition With the operational model



**Two** ligands (j = 1, 2) and **two** measured responses (i = 1, 2): Each dose-response data is fitted with the operational model :

$$y_{ij} = E_i \frac{\tau_{ij}^{n_i} [L]^{n_i}}{([L] + Ka_{ij})^{n_i} + \tau_{ij}^{n_i} [L]^{n_i}}.$$

#### Bias definition With the operational model




**Two** ligands (j = 1, 2) and **two** measured responses (i = 1, 2): Each dose-response data is fitted with the operational model :

$$y_{ij} = E_i \frac{\tau_{ij}^{n_i} [L]^{n_i}}{([L] + Ka_{ij})^{n_i} + \tau_{ij}^{n_i} [L]^{n_i}}$$

For a given response *i*, we calculate  $\Delta_i \log(\tau/K_a) = \log(\tau_{i2}/Ka_{i2}) - \log(\tau_{i1}/Ka_{i1}).$ 

#### Bias definition With the operational model




**Two** ligands (j = 1, 2) and **two** measured responses (i = 1, 2): Each dose-response data is fitted with the operational model :

$$y_{ij} = E_i \frac{\tau_{ij}^{n_i} [L]^{n_i}}{([L] + Ka_{ij})^{n_i} + \tau_{ij}^{n_i} [L]^{n_i}}$$


For a given response *i*, we calculate  $\Delta_i \log(\tau/K_a) = \log(\tau_{i2}/Ka_{i2}) - \log(\tau_{i1}/Ka_{i1}).$ The **Bias** is then defined by

$$\Delta\Delta\log( au/ extsf{K}_{a})=\Delta_{2}\log( au/ extsf{K}_{a})-\Delta_{1}\log( au/ extsf{K}_{a})$$


#### Statistical consideration




Raue A., et al. *Bioinformatics* (2015)




 A strong bias is usually 'apparent' on dose-response curves or bias plot



But there may be counter-intuitive situation...




But there may be counter-intuitive situation...



But there may be counter-intuitive situation...

... and those situations occur in real life!



What is biased signaling?

Some examples

Bias calculus - standard method : operational model

Some extension to bias calculus

Biased signaling using dynamical model

# Time-dependent bias


# The role of kinetic context in apparent biased agonism at GPCRs

Carmen Klein Herenbrink<sup>1</sup>, David A. Sykes<sup>2</sup>, Prashant Donthamsetti<sup>3,4</sup>, Meritxell Canals<sup>1</sup>, Thomas Coudrat<sup>1</sup>, Jeremy Shonberg<sup>5</sup>, Peter J. Scammells<sup>5</sup>, Ben Capuano<sup>5</sup>, Patrick M. Sexton<sup>1</sup>, Steven J. Charlton<sup>2</sup>, Jonathan A. Javitch<sup>3,4,6</sup>, Arthur Christopoulos<sup>1</sup> & J Robert Lane<sup>1</sup>

- Bias value may change according to the response time after stimulation.
- Kinetic explanation : Ligands with a slow binding kinetics may have changing bias value according to time.



Klein Herenbrink et al., *Nat. Commun* (2016)



# Other extensions

Dose-dependent bias



- Barak and Peterson et al., *Biochem.* (2012)
- Extension of the operational model




Kenakin, Chem. Rev. (2017)

 Method based on Intrinsic activities and rank ordering



Onaran et al., *Sci. Rep.* (2017)



What is biased signaling?

Some examples


Bias calculus - standard method : operational model

Some extension to bias calculus

Biased signaling using dynamical model


# Dynamic data (on FHSR in HEK cells)

Instead of focusing on dose-response curves, we deal with several doses kinetic experiments (here : induced BRET data)




# Dynamic data (on FHSR in HEK cells)


Instead of focusing on dose-response curves, we deal with several doses kinetic experiments (here : induced BRET data)




Original "raw" data




#### "Adjusted" data




"Adjusted" data




I)We start with a sufficiently detailed chemical reaction network




I)We start with a sufficiently detailed chemical reaction network to accurately fit the data (one separate model for each Ligand)




II) We fit all data at once, using some common parameters (initial concentration of molecules, measurement parameters...) and some different ones (kinetic parameters...)



II) We fit all data at once, using some common parameters (initial concentration of molecules, measurement parameters...) and some different ones (kinetic parameters...)




III) We use  $L^1$ -penalization to find the needed ligand specific parameters






Steiert, Timmer and Kreutz, Bioinformatics (2016)

III) We use  $L^1$ -penalization to find the needed ligand specific parameters, keeping the fit 'as good as before'




Steiert, Timmer and Kreutz, Bioinformatics (2016)

IV) After re-optimization, the set of distinct (ligand-specific) kinetic parameters gives us an accurate description of ligand specificity.




V) Significant differences between parameters is assessed by PLE





C1 is biased towards  $\beta\text{-arr,}$  compared to cAMP, in comparison to FSH.

# Practical problems...





#### Practical problems...






We obtain a slightly worse fit







And "better" parameter identifiability



C1 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH.




We systematically calculate bias value using standard method (operational model on dose-response curves :)




Bias=2.3 : C1 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH.

We systematically calculate bias value using standard method (operational model on dose-response curves :)




Bias=2.64 : C1 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH.

We systematically calculate bias value using standard method Different times gives (slightly) different bias values



C1 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH

We systematically calculate bias value using standard method Uncertainty can be large according to the time of measurement



- Notion of signaling bias to quantify differential activation of several pathways by a Ligand at a given receptor.
- Standard quantification has several drawbacks (no time, limited to sigmoid scenario,..).
- We gave a kinetic interpretation of Ligand biased, which rely on dynamic (ODE) modeling and parameter estimation with L<sup>1</sup> penalization.

#### Thanks for your attention !

- Notion of signaling bias to quantify differential activation of several pathways by a Ligand at a given receptor.
- Standard quantification has several drawbacks (no time, limited to sigmoid scenario,..).
- We gave a kinetic interpretation of Ligand biased, which rely on dynamic (ODE) modeling and parameter estimation with L<sup>1</sup> penalization.
- Any other ideas how to define *bias*?
- How to deal with "fuzzy/noisy" PLE?
- How to deal with non uniqueness of the penalized solution?
- How to perform a model reduction that would lead to both a satisfactory fit and identifiable parameters?

